Almirall: posts nine-month net profit thanks to key brands
(CercleFinance.com) - Almirall reported nine-month profit on Monday, helped by growth in the sales of its dermatology drugs, which triggered a slight rise in its shares.
Shares of the Barcelona-based drugmaker are currently up 0.5% at 17.15 euros on the Madrid Stock Exchange.
This morning Almirall reported net income of 93.2 million euros for the first nine months of the year, compared with 99.7 million euros a year ago.
Nine-month revenue grew by 4% to 584 million euros, as the company benefited from new launches and a solid performance of its core business.
Dermatology sales amounted to 197.7 million euros, including European sales of 142 million euros, helped by the strong performance of key brands, such as the psoriais drug Skilarence and antifungal treatment Ciclopoli.
The group said it was "encouraged" by this strong business momentum, driven by key brands.
Almirall - which has now closed the acquisition of the former Allergan's medical dermatology portfolio in the US - expects 2018 revenues to grow in the mid-to-high single-digit range on a CER basis, versus an initial estimation of mid-single-digit growth.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
Shares of the Barcelona-based drugmaker are currently up 0.5% at 17.15 euros on the Madrid Stock Exchange.
This morning Almirall reported net income of 93.2 million euros for the first nine months of the year, compared with 99.7 million euros a year ago.
Nine-month revenue grew by 4% to 584 million euros, as the company benefited from new launches and a solid performance of its core business.
Dermatology sales amounted to 197.7 million euros, including European sales of 142 million euros, helped by the strong performance of key brands, such as the psoriais drug Skilarence and antifungal treatment Ciclopoli.
The group said it was "encouraged" by this strong business momentum, driven by key brands.
Almirall - which has now closed the acquisition of the former Allergan's medical dermatology portfolio in the US - expects 2018 revenues to grow in the mid-to-high single-digit range on a CER basis, versus an initial estimation of mid-single-digit growth.
Copyright (c) 2018 CercleFinance.com. All rights reserved.